Blue Calypso, Inc. Common (PK:BCYP)
Business Focus: N/A
Oct 25, 2021 07:39 am ET
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today...
Oct 21, 2021 07:00 am ET
Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics
MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders, at a Spec
Oct 06, 2021 07:00 am ET
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb™ platform and pipeline of clinical and preclinical programs.
Oct 04, 2021 07:00 am ET
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced that the first patient has been dosed with SAB-185 in the Phase 3 ACTIV-2 COVID-19 trial.
Sep 28, 2021 07:00 am ET
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB’s financial operations and key supporting functions and will work with the senior management team to drive SAB’s growth.
Sep 24, 2021 07:00 am ET
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3. SAB-185 is a fully-human, specifically-targeted, broadly-neutralizing polyclonal antibody therapeutic candidate for
Sep 23, 2021 07:00 am ET
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to, among other matters, allow its stockholders to approve the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc., (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antib
Sep 22, 2021 07:00 am ET
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that the U.S. Department of Defense (DoD) has awarded the company an additional $60.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program for advanced clinical development through licensure and commercial manufacturing for SAB-185, the company’s therapeutic candidate for the treatment of COVID-19. The new award expands the scope o
Sep 15, 2021 07:00 am ET
SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of enrollment in its Phase 2a clinical trial evaluating the safety and efficacy of SAB-176 in a challenge study. SAB-176 is a novel anti-influenza human immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza. It is a high-potency multivalent human polyclonal antibody therapeutic desi
Sep 08, 2021 07:00 am ET
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at two upcoming virtual investor conferences in September. Presentation details can be found below:
Aug 18, 2021 11:56 am ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of RIVE, IACB, BCYP, and RFL Mergers
Rigrodsky Law, P.A. announces that it is investigating: Riverview Financial Corporation (NASDAQ GM: RIVE) regarding possible breaches of fiduciary duties and other violations of law related to Riverview’s agreement to merge with Mid Penn Bancorp,...
Aug 11, 2021 07:00 am ET
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics without the need for human donors, today announced the publication of data showing that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 infections, demonstrates effective and potent neutralization of multiple SARS-CoV-2 variants of concern, including the Delta and Lambda variants. The nonclinical study,
Jul 15, 2021 07:00 am ET
Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics
MIAMI, July 15, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today reported that Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics, Inc. (SAB), presented at the Ladenburg Thalmann Annual Healthcare Conference this week. The presentation was webcast live and is available for replay for 90 days at https://wsw.com/webcast/ladenburg7/sab.bio/2863978.
Jul 10, 2021 04:00 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of ALTA, BCYP, IKNX and STMP
Altabancorp (NasdaqCM: ALTA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of ALTA with GBCI. If you are an investor, and would like information about...
Jul 09, 2021 07:00 am ET
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, July 13 at 5:00 p.m. ET.
Jul 07, 2021 07:00 am ET
Big Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB Biotherapeutics
MIAMI, July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company that is developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal
Jun 25, 2021 03:22 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Big Cypress Acquisition Corp. Merger
Rigrodsky Law, P.A. announces that it is investigating Big Cypress Acquisition Corp. (“Big Cypress”) (NASDAQ CM: BCYP) regarding possible breaches of fiduciary duties and other violations of law related to Big Cypress’ agreement to merge with SAB...
Jun 24, 2021 11:21 am ET
Moore Kuehn Encourages SNNY, GSAH, THMA and BCYP Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Jun 22, 2021 06:00 am ET
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerg
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-human polyclonal antibodies at scale, and Big Cypress Acquisition Corp. (NASDAQ: BCYP), a blank check company focused on innovative biopharmaceutical firms, today announced that they have entered into a definitive business combination agreement. Upon closing of the proposed transaction, the combined company will operate as SAB Biotherapeutics and will continue to operate under the SAB management team, with Big Cypress Acquisition Corp.’s Samuel J
Feb 04, 2021 08:00 am ET
Big Cypress Acquisition Corp. Announces Separate Trading of its Shares of Common Stock and Redeemable Warrants Commencing February 9, 2021
Big Cypress Acquisition Corp. (the "Company") announced that, commencing February 9, 2021, holders of the units sold in the Company's initial public offering of 11,500,000 units may elect to separately trade the shares of common stock and...
Jan 14, 2021 12:10 pm ET
Big Cypress Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, which Includes Full Exercise of the Underwriters' Over-Allotment Option
Big Cypress Acquisition Corp. (the "Company") announced today that it closed its initial public offering of 11,500,000 units, which includes the full exercise of the underwriters’ over-allotment option. The units were sold at $10.00 per unit,...
Nov 10, 2016 04:01 pm ET
Blue Calypso Reports Third Quarter 2016 Financial Results
DALLAS, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for product brands and brick-and-mortar retailers, reported financial and operating results for its third quarter ended September 30, 2016....
Oct 20, 2016 03:00 pm ET
Blue Calypso to Host Third Quarter 2016 Conference Call on Thursday, November 10, 2016 at 4:30 p.m. ET
DALLAS, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for product brands and brick-and-mortar retailers, will hold a conference call on Thursday, November 10, 2016 at 4:30 p.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2016. Financial results will be issued in a press release prior to the call. ...
Oct 18, 2016 08:31 am ET
Blue Calypso Announces Board Transition
DALLAS, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for product brands and brick-and-mortar retailers, announced that Harold ‘Hal’ Brierley, chairman of the board of directors has stepped down from his role as chairman of the board and will transition to a senior advisory board member due to a recently announced commitment to the Brierley Institute for Customer Engagement at Southern Methodist University (SMU). Andrew Levi, founder and CEO will be appointed to chairman of the board...
Aug 10, 2016 04:01 pm ET
Blue Calypso Reports Second Quarter 2016 Financial Results
DALLAS, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for product brands and brick-and-mortar retailers, reported financial and operating results for its second quarter ended June 30, 2016....
Jul 26, 2016 08:31 am ET
Blue Calypso Appoints Hal Brierley as Chairman of the Board
DALLAS, July 26, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, has appointed Harold ‘Hal’ Brierley, as chairman of the board of directors, succeeding Founder and CEO Andrew Levi, who will remain on the board as a director and continue as CEO. Brierley has served as an independent advisor to the board since May 2016 and now serves as its first independent chairman....
Jul 25, 2016 08:31 am ET
Blue Calypso to Host Second Quarter 2016 Conference Call on Wednesday, August 10, 2016 at 4:30 p.m. ET
DALLAS, July 25, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, will hold a conference call on Wednesday, August 10, 2016 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2016. Financial results will be issued in a press release prior to the call. ...
May 16, 2016 04:01 pm ET
Blue Calypso Reports First Quarter 2016 Financial Results
DALLAS, May 16, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, reported financial and operating results for its first quarter ended March 31, 2016....
May 09, 2016 04:01 pm ET
Blue Calypso Postpones First Quarter 2016 Earnings Release and Conference Call
DALLAS, May 09, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, postponed its first quarter 2016 earnings release and conference call to Monday, May 16, 2016 at 4:30 p.m. Eastern time to allow additional time to finalize its financial results for the first quarter ended March 31, 2016. Financial results will be issued in a press release prior to the call and the company will file its Quarterly Report on Form 10-Q on May 16, 2016....
May 02, 2016 08:31 am ET
Blue Calypso to Host First Quarter 2016 Conference Call on Wednesday, May 11, 2016 at 4:30 p.m. ET
DALLAS, May 02, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, will hold a conference call on Wednesday, May 11, 2016 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2016. Financial results will be issued in a press release prior to the call. ...
Apr 28, 2016 08:31 am ET
Blue Calypso Receives Strategic Investment from Loyalty Program Innovator Hal Brierley
DALLAS, April 28, 2016 (GLOBE NEWSWIRE) -- Blue Calypso, Inc. (OTCQB:BCYP), an innovator of mobile consumer activation, engagement and social advocacy solutions for manufacturers and brick-and-mortar retailers, has closed a $1 million strategic investment and senior advisory agreement with Harold ‘Hal’ Brierley, Chairman and CEO of The Brierley Group, a loyalty consulting and venture development firm. ...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.